Annual Meeting of Japanese Society of Pediatric Cardiology and Cardiac Surgery

Transcatheter pulmonary valve implantation (TPVI) is one of the most exciting recent developments in the treatment of congenital heart disease and has evolved to become an attractive alternative to surgery in patients with right ventricular outflow tract (RVOT) dysfunction. Since Bonhoeffer et al. reported the first percutaneous implantation of the Melody valve for conduit in 2000, TPVI achieved satisfactory performance in patients with conduit dysfunction. After the introduction of TPVI for conduit, the current trends of TPVI development focus on TPVI for native RVOTR and accessory devices for safety implantation. However, due to the delayed introduction of TPVI to Japan, no accessory devices for TPVI, such as Dryseal sheath, pre-stent for RVOTR, and Vida balloon, have been introduced. We will review and discuss the history of development, current circumstances, and future direction of TPVI in Japan.